Drug DISCOVERY in 2000

For the opening issue of Drug Discovery Today (DDT) in the 21st century, we would like to express our sincere gratitude to all the individuals who have made the journal a success with their invaluable contributions since its launch in January 1996. We wish to express our deep appreciation for the past and present Editorial Board members and the authors and referees of the various published articles. As a special note, we would also like to extend our heartfelt thanks to the previous Editor David Hughes, Assistant Editors Henriette Willems and Simon Fenwick, and Editorial Administrator Rachel DeWachter. The outstanding effort of all the above individuals has resulted in the journal becoming the premier publication in the drug discovery field. We would like to start the New Year by encouraging proposals for our Editorial, Reviews, Update and Profiles sections. In addition, constructive feedback concerning the content of the journal is always welcome. All proposals and letters should be sent to the Editor at the address on the contents page or sent by e-mail to ddt@current-trends.com



The editorial team are:
(Below) from right to left (front row)
Debbie Tranter (Editor) and Rebecca
Lawrence (Assistant Editor), (back row)
Vaughan Collinson (Production
Coordinator) and Ben Ramster (Editorial
Administrator).
(Left) Andrew Lloyd (Monitor Editor).



Current Editorial Board Members:

David Bailey

Incyte Pharmaceuticals, Palo Alto, CA, USA

Alastair Binnie

Bristol-Myers Squibb Pharmaceuticals, Wallingford, CT, USA

Dale L. Boger

The Scripps Research Institute, La Jolla, CA, USA

David Cavalla

Arachnova, Cambridge, UK

Maurice Dickins

GlaxoWellcome, Ware, UK

Jürgen Drews

Orbimed Advisors, NY, USA

Mark Dyer

Novartis Pharma, Basel, Switzerland

Terry Hart

Novartis Institute for Medical Sciences, London, UK

Jack Heinemann

University of Canterbury, New Zealand

Christopher M. Hill

Roche Research Centre, Welwyn Garden City, UK

Nick Hird

Takeda Chemical Industries, Osaka, Japan

Roger Lahana

Synt:em, Nîmes, France

Mark Murcko

Vertex Pharmaceuticals, Cambridge, MA, USA

Martin Page

Oxford GlycoSciences, Abingdon, UK

Michael R. Pavia

Millennium Pharmaceuticals, Cambridge, MA, USA

Mark V. Rogers

Pfizer Central Research, Sandwich, UK

Dennis A. Smith

Pfizer Central Research, Sandwich, UK

Paul Spence

Wyeth-Ayerst Research, Princeton, NJ, USA

Harry Stylli

Aurora Biosciences, La Jolla, CA, USA

David Szymkowski

Roche Bioscience, Palo Alto, CA, USA

Nick Terrett

Pfizer Central Research, Sandwich, UK

Yoshio Tsujita

Sankyo Co, Tokyo, Japan

B. Boris Vargaftig

Institut Pasteur, Paris, France

Mark Whittaker

British Biotech Pharmaceuticals, Oxford, UK